View Author
patient protease monotherapy therapy resistance treatment study infection agent lopinavir inhibitor failure mutation ef ficacy haart mycobacterium avium mycobacterium avium concentration lpv /r monotherapy combination hiv-rna trial clarithromycin analysis activity virologic failure amikacin ficacy mycobacterial liposomes regimen result growth virologic lpv /r antimycobacterial effect /liter protease inhibitor mutations 24 weeks bactericidal exposure antimycobacterial agents ethambutol mycobacteria signi 21 days l 76v antimicrob protease inhibitor monotherapy addition susceptibility chemother 10 days virus strain sample m 46i ritonavir-boosted therapy failure agents chemother number delivery mycobacterial infections bactericidal activity 50 copies /ml mac infection /ritonavir drug delivery phase substitution antimicrobial plasma organ 16 mg /liter lopinavir resistance as-treated analysis antiretroviral mouse model
